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Abstract 
Study Objective 
Tools proposed to triage patient acuity in COVID-19 infection have only been validated in hospital 
populations. We estimated the accuracy of five risk-stratification tools recommended to predict 
severe illness and compare accuracy to existing clinical decision-making in a pre-hospital setting.  
Methods 
An observational cohort study using linked ambulance service data for patients attended by EMS 
crews in the Yorkshire and Humber region of England between 18th March 2020 and 29th June 2020 
was conducted to assess performance of the PRIEST tool, NEWS2, the WHO algorithm, CRB-65 and 
PMEWS in patients with suspected COVID-19 infection. The primary outcome was death or need for 
organ support. 
Results 
Of 7549 patients in our cohort, 17.6% (95% CI:16.8% to 18.5%) experienced the primary outcome. 
The NEWS2, PMEWS, PRIEST tool and WHO algorithm identified patients at risk of adverse outcomes 
with a high sensitivity (>0.95) and specificity ranging from 0.3 (NEWS2) to 0.41 (PRIEST tool). The 
high sensitivity of NEWS2 and PMEWS was achieved by using lower thresholds than previously 
recommended. On index assessment, 65% of patients were transported to hospital and EMS 
decision to transfer patients achieved a sensitivity of 0.84 (95% CI 0.83 to 0.85) and specificity of 
0.39 (95% CI 0.39 to 0.40).  
Conclusion 
Use of NEWS2, PMEWS, PRIEST tool and WHO algorithm could improve sensitivity of EMS triage of 
patients with suspected COVID-19 infection. Use of the PRIEST tool would improve sensitivity of 
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Background 
Emergency Medical Service (EMS) and other urgent and emergency care practitioners assessing 
patients with suspected COVID-19 infection in the community, must rapidly determine whether 
patients need treatment in hospital or can safely remain at home. The overall risk of mortality in 
patients with confirmed infection is around 1% and if conveyance is too liberal, hospitals could be 
overwhelmed by patients who require no specific treatment.1 However, failing to identify a patient 
at risk of serious deterioration could lead to avoidable harm.2  
Prognostic research has almost exclusively been conducted in hospital settings and current national 
and international guidelines for risk-stratification of patients with suspected COVID-19 in the 
community are consensus based.
1, 3-5
  Clinical acuity scores, such as the UK Royal College of 
Physicians Early Warning Score, version 2 (NEWS2), have been suggested in some guidelines as a 
way to risk-stratify patients with suspected COVID-19 infection in the community.6 The WHO 
decision-making algorithm for respiratory infection and CRB-65 are used to risk-stratify patients with 
bacterial pneumonia and PMEWS for use in patients with influenza.7-9 However, the accuracy of 
these risk-stratification tools has only been validated in hospitalised or non-COVID populations.    
NEWS2 has shown good prediction of adverse outcome in patients attending the Emergency 
Department (ED) with suspected COVID-19. 7 The PRIEST tool was derived by adding age, sex, and 
performance status to NEWS2, and validation showed improved prediction compared to NEWS2 
alone.
10, 11
 Validation of the PRIEST tool, NEWS2 and other clinical risk-stratification tools 
recommended for use in hospital in a community setting,7, 10, 12-14 could identify the most accurate 
means to triage need for hospitalisation, thereby reducing unnecessary hospital attendances and 
improve the identification of those most at risk of serious adverse outcomes. 
Our study aimed to: 
1) Estimate the accuracy of risk-stratification tools recommended to predict severe illness in 
adults with suspected COVID-19 infection in a pre-hospital setting.  
2) Compare the accuracy of risk-stratification tools to existing clinical decision-making around 
transport to hospital.   
Methods 
Study Design 
This observational cohort study used linked routinely collected EMS data to assess the accuracy in a 
community setting of five clinical risk-stratification tools (PRIEST tool, NEWS2, WHO algorithm, CRB-
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65 and PMEWS) recommended for use in hospitalised patients with COVID-19 or similar respiratory 




Patients with suspected COVID-19 infection attended by emergency medical services provided by 
Yorkshire Ambulance Service NHS Trust (YAS).  Emergency services provided by YAS covers a region 
in the north of England of approximately 6,000 square miles and with a population of 5.3 million. 
Data Sources and linkage 
EMS providers complete an electronic patient report form (ePRF) each time they attend an 
emergency call, which records presenting patient characteristics and clinical care in a standardised 
manner. YAS provided a dataset of ePRF data for all EMS responses between the 18th March 2020 
and 29th June 2020 where the attending ambulance staff recorded a clinical impression of suspected 
or confirmed COVID-19 infection. The dataset consisted of patient identifiers, demographic data, 
measured physiological parameters, other available clinical information and the outcome of the 
assessment (including whether the patient was conveyed to hospital).  
Health and social care data relating to the population in England within the UK National Health 
Service (NHS) is managed by NHS Digital. We provided patient identifiers to NHS Digital to trace 
patients in our cohort and supply additional individual level demographic, co-morbidity and outcome 
data. NHS Digital identified records in their collections belonging to patients in our cohort, and 
provided data on patient demographics, limited COVID-related general practice (GP) records, 
emergency department attendances, hospital inpatient admissions, critical care periods, and death 
registrations from the UK Office of National Statistics.  
YAS and NHS Digital removed records where patients indicated that they did not wish their data to 
be used for research purposes, via the NHS data opt-out service.
15
 The study team also excluded 
patients who had opted out of any part of the PRIEST study and those with inconsistent records (e.g. 
multiple deaths recorded or death before latest activity). Patient identifiers across all datasets were 
replaced with a consistent pseudo-identifier to enable the identification and linkage of records 
belonging to the same patient across all datasets but without revealing any patient’s identity. 
Inclusion Criteria 
Our final cohort consisted of all adult (aged 16 years and over) patients at time of first (index) EMS 
attendance between 18th March and 29th June 2020, in which the attending ambulance staff 
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recorded a clinical impression of suspected or confirmed COVID-19 infection, and who were 
successfully traced by NHS Digital. 
Outcome 
The primary outcome was death, renal, respiratory, or cardiovascular organ support (identified from 
death registration and critical care data) at 30 days from index attendance.  
 




Physiological parameters were extracted from the first (primary) set of clinical observations 
recorded by the ambulance crew. Consistent with methods used to estimate the Charlson 
comorbidity index from the available routine data, comorbidities were included if recorded 12 
months before the index EMS attendance.16, 17 In a similar way, only immunosuppressant drug 
prescriptions documented in GP records within 30 days before the index attendance, contributed to 
the immunosuppression co-morbidity variable. Pregnancy status was based on GP records recorded 
in the previous 9 months. Frailty in patients older than 65 years was derived from the latest 
recorded Clinical Frailty Scale (CFS) score (if recorded) in the electronic GP records prior to index 
attendance.18 Patients under the age of 65 years were not given a CFS score since it is not validated 
in this age group. However, if a CFS score was required to calculate a triage tool and the patient was 
under the age of 65, it was assumed to be 1. Performance status was estimated from the CFS.  
Analysis 
We retrospectively applied the 5 triage tools to our cohort to assess their accuracy for the primary 
and secondary outcomes.7, 10, 12-14 Supplementary Material 1 provides details of scoring and handling 
missing data for the triage tools. For each tool we plotted the receiver operating characteristic (ROC) 
curve and calculated the area under the ROC curve (c-statistic) for discriminating between patients 
with and without adverse outcome. We calculated sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) at the following pre-specified decision making thresholds 
based on recommended or usual use: 0 vs 1+ CRB-65; 0–1 vs 2+ NEWS2; 0–2 vs 3+ PMEWS; 0–4 vs 
5+ PRIEST; 0 vs 1 WHO score. The NEWS2 and PMEWS thresholds used are lower than previously 
proposed (0–3 vs 4+ NEWS and 0–3 vs 4+ PMEWS) for triaging patient acuity, and are based on the 
assessment of their performance in a UK ED population of patients with suspected COVID-19 
infection, where higher thresholds gave sub-optimal sensitivity.19 The WHO algorithm and CRB-65 
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are positive if any criterion is positive. These tools were compared to the sensitivity, specificity, PPV 
and NPV of EMS clinicians’ decision to transfer patients to hospital. All analyses were based on 
assessment during the index EMS attendance and completed with SAS v9.4.   
Ethical Approval 
 
The North West—Haydock Research Ethics Committee gave a favourable opinion on the PAINTED 
study on 25
th
 June 2012 (reference 12/NW/0303) and on the updated PRIEST study on 23rd March 
2020, including the analysis presented here. The Confidentiality Advisory Group of the NHS Health 
Research Authority granted approval to collect data without patient consent in line with Section 251 
of the National Health Service Act 2006. Access to data collected by NHS Digital was recommended 
for approval by its Independent Group Advising on the Release of Data (IGARD) on 11
th
 September 
2021 having received additional recommendation for approval for access to GP records from the 
Profession Advisory Group (PAG) on 19th August 2021. 
 
Patient Public Involvement 
 
The Sheffield Emergency Care Forum (SECF) is a public representative group interested in emergency 
care research.
20
 Members of SECF advised on the development of the PRIEST study and two 




All totals presented from NHS Digital derived data sets (sex, number of current medications, 
comorbidities, clinical frailty scores and outcomes) are rounded to the nearest 5, with small numbers 




Figure 1 and Table 1 summarise study cohort derivation and the characteristics of the 7,549 included 
individual adult patients. In total, 1,330 patients (17.6%, 95% CI:16.8% to 18.5%) experienced the 
primary outcome (death or organ support) and 1,065 (14.1%, 95% CI: 13.4% to 14.9%), the 
secondary outcome (death). Of the 7, 549 patients, the decision was made to transport 4,905 (65%) 
to hospital at index attendance. Of those, 1,120 (22.9%) experienced the primary adverse outcome. 
Of those not transported to hospital, 210 (7.9%) had an adverse outcome. Within the cohort, 3,925 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 29, 2021. ; https://doi.org/10.1101/2021.07.27.21261031doi: medRxiv preprint 
patients (52%, 95% CI:50.9% to 53.1%) were admitted as inpatients and 2,785 (36.9%, 95% CI: 35.8% 
to 38%) had a diagnosis of COVID confirmed in hospital (since unrestricted community testing was 
not available until the 18/05/2020) within 30 days of index EMS attendance.  
 
Table 1. Patient characteristics by outcome 
Characteristic Statistic/level Adverse outcome No adverse outcome Total 
N 1330 (17.6%)* 6220 (82.4%)* 7549 
Age (years)* Mean (SD) 74.5 (15.4) 56.9 (19.4) 60 (20) 
Median (IQR) 78 (65,86) 56 (42,73) 59 (45,77) 
Range 19 to 103 16 to 105 16 to 105 
Sex* Male 760 (57.3%) 2825 (45.4%) 3590 (47.5%) 
 Female 570 (42.7%) 3390 (54.6%) 3960 (52.5%) 
Number of 
current 
medications* N 1330 6220 7549 
 Mean (SD) 4.5 (3.3) 3.2 (3.3) 3.4 (3.3) 
 Median (IQR) 4 (2,7) 2 (0,5) 3 (0,6) 
 Range 0 to 19 0 to19 0 to19 
Comorbidities* 
Cardiovascular 
disease 95 (7%) 290 (4.6%) 380 (5.1%) 
 
Chronic respiratory 
disease 375 (28%) 1855 (29.8%) 2230 (29.5%) 
 Diabetes 390 (29.2%) 995 (16%) 1380 (18.3%) 
 Hypertension 610 (45.8%) 1765 (28.4%) 2375 (31.4%) 
 Immunosuppression 280 (21.1%) 930 (15%) 1215 (16.1%) 
 Active malignancy 60 (4.6%) 115 (1.9%) 180 (2.3%) 
 Renal impairment 55 (4.1%) 125 (2%) 180 (2.4%) 
 Stroke 30 (2.3%) 85 (1.4%) 115 (1.5%) 
Clinical frailty* N/A (age <65 years) 330 (47.5%) 3985 (86.4%) 4310 (81.3%) 
 Missing 645 1605 2250 
 1-3 20 (4.7%) 40 (6.4%) 60 (5.8%) 
 4-6 75 (20.5%) 240 (37.7%)  310 (31.4%) 
 7-9 270 (74.8%) 350 (55.9%) 620 (62.8%) 
AVPU Missing 13 58 71 
 Alert 1002 (76%) 5860 (95.1%) 6862 (91.8%) 
 Confusion 125 (9.5%) 188 (3.1%) 313 (4.2%) 
 Voice 100 (7.6%) 84 (1.4%) 184 (2.5%) 
 Pain 64 (4.9%) 21 (0.3%) 85 (1.1%) 
 Unresponsive 27 (2%) 7 (0.1%) 34 (0.5%) 
Glasgow Coma 
Scale N 1297 6085 7382 
 Mean (SD) 13.7 (2.4) 14.8 (0.8) 14.6 (1.3) 
 Median (IQR) 15 (14,15) 15 (15,15) 15 (15,15) 
 Range 3 to 15 3 to 15 3 to 15 
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Characteristic Statistic/level Adverse outcome No adverse outcome Total 
Diastolic BP 
(mmHg) N 1278 6029 7307 
 Mean (SD) 76.7 (17.7) 84.5 (15.9) 83.1 (16.5) 
 Median (IQR) 76 (65,87) 84 (74,94) 83 (72,93) 
 Range 0 to 193 22 to 167 0 to 193 
Systolic BP 
(mmHg) N 1277 6032 7309 
 Mean (SD) 133.2 (25.8) 140.2 (23.2) 139 (23.9) 
 Median (IQR) 132 (116,148) 139 (124,153) 138 (123,152) 
 Range 65 to 238 33 to 237 33 to 238 
Pulse rate 
(beats/min) N 1303 6130 7433 
 Mean (SD) 100.2 (22.5) 96 (19.5) 96.7 (20.1) 
 Median (IQR) 99 (84,115) 94 (82,109) 95 (82,110) 
 Range 38 to 194 7 to 190 7 to 194 
Respiratory  
rate 
(breaths/min) N 1315 6145 7460 
 Mean (SD) 30.1 (10) 23.1 (6.9) 24.4 (8) 
 Median (IQR) 28 (22,36) 20 (18,26) 22 (18,28) 
 Range 0 to 76 0 to 84 0 to 84 
Oxygen 
saturation Missing 36 109 145 
 >95% on air 142 (11%) 3532 (57.8%) 3674 (49.6%) 
 94-95% on air 134 (10.3%) 854 (14%) 988 (13.3%) 
 92-93% on air 109 (8.4%) 449 (7.3%) 558 (7.5%) 
 
<92% on air or O2 
given 910 (70.3%) 1274 (20.9%) 2184 (29.5%) 
Blood glucose 
(mmol/L) N 982 4021 5003 
Mean (SD) 8.1 (4) 6.9 (3.2) 7.2 (3.4) 
Median (IQR) 6.8 (5.6,9) 6 (5.2,7.3) 6.2 (5.2,7.7) 
Range 0.9 to 35 1.1 to 33.8 0.9 to 35 
Temperature 
(°C) N 1301 6115 7416 
Mean (SD) 38.1 (1.2) 37.8 (1.1) 37.8 (1.1) 
Median (IQR) 38.2 (37.4,38.9) 37.7 (37,38.5) 37.8 (37,38.6) 
Range 32 to 42 34 to 41.7 32 to 42 
*To comply with NHS digital disclosure guidance totals for these variables are rounded to the nearest 5, which may result 
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Triage tool performance 
 
Sensitivity, specificity, positive and negative predictive values for predicting the primary composite 
outcome using pre-defined score thresholds are provided in Table 2 and the secondary outcome of 
death in Table 3. Sensitivity and specificity statistics are provided for every score threshold in 
Supplementary Material 2. The ROC curves for these analyses are shown in Figures 2–3.  
EMS attendances by YAS between 18th March 
and 29th June 2020 with clinical impressions of 
COVID-19 infection 
N = 8,605 
  
Attendances for which it was not 
possible to trace patient’s identity 
N = 333 
Linkable YAS attendances  
N = 8,272 
Cohort of individual patients 
N = 7,709 
Final study population 
N = 7, 549 
Multiple calls single patient or 
excluded patients 
N = 563 
Aged<16 
N = 160 
NHS Digital routine data 
sources: APC, CC, ECDS, 
DEMO, DR & GDPPR 
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Table 2. Triage tool diagnostic accuracy statistics (95% CI) for predicting any adverse outcome 
Tool N* C-statistic Threshold 
Proportion 
with score 

































































*Patients with 3 or more missing triage tool parameters were excluded from analysis when estimating performance  
The PRIEST tool was robust to the removal of the performance status parameter; when doing so the 
C-statistic remained at 0.83 (95% CI 0.82 to 0.84). EMS decision to transfer patients to hospital had a 
sensitivity of 0.84 (95% CI 0.83 to 0.85) and specificity 0.39 (95% CI 0.39 to 0.40) for the primary 
outcome. The positive predictive value (PPV) was 0.23 (95% CI 0.22 to 0.23) and the negative 
predictive value (NPV) 0.92 (95% CI 0.92 to 0.92). Hypothetical use of any of the 5 triage tools would 
have achieved a higher sensitivity than the decision to transfer to hospital by the EMS crews within 
the cohort, but in the case of NEWS2, the WHO algorithm and PMEWS, this was at a cost of a lower 
specificity (Table 2). Of the tools assessed at the pre-determined thresholds, CRB-65 achieved the 
highest specificity but at the cost of sensitivity, and the PRIEST tool achieved a balance between 
both sensitivity, specificity and C-statistic of 0.83 (95% CI 0.82 to 0.84). The triage tools generally 
demonstrated better discrimination (except NEWS2) and a higher sensitivity for the secondary 
outcome, but a lower specificity (Table 3). 
Table 3. Triage tool diagnostic accuracy statistics (95% CI) for predicting death within 30 days 
Tool N* C-statistic Threshold 
Proportion 
with score 

































































*Patients with 3 or more missing triage tool parameters were excluded from analysis when estimating performance  
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Figure 2. ROC curves showing triage tool performance for predicting any adverse outcome
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The NEWS2, PMEWS, PRIEST tool and WHO algorithm identified patients at risk of adverse outcome 
with high sensitivity (>0.95) and specificity ranging between 0.3 (NEWS2) and 0.41 (PRIEST tool). 
They are therefore potentially suitable for use as triage tools to select patients for transfer to 
hospital. The high sensitivity of NEWS2 and PMEWS was achieved by using lower thresholds (NEWS2; 
0–1 vs 2+ and PMEWS; 0–2 vs 3+) than previously recommended, based upon performance in an ED 
population of patients with suspected COVID-19 infection.19 
At index attendance, 65% of patients were transported to hospital. Although a useful comparator for 
triage tool performance, the observed accuracy of EMS decision-making to transfer patients to 
hospital does not account for clinical best interest decisions not to covey patients to hospital who 
subsequently deteriorated, or patient wishes not to be conveyed. The sensitivity (0.84, 95% CI 0.83 
to 0.85) and specificity (0.39, 95% CI 0.39 to 0.40) achieved by EMS decision making is nonetheless 
similar to that of tools used to triage undifferentiated patient acuity in the ED.
21
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To be clinically useful to EMS crews, the use of a triage tool would need to improve upon the existing 
sensitivity of clinical decision making, thereby reducing the risk of not transporting a patient to 
hospital who subsequently deteriorates, without leading to a disproportionately large increase in 
hospital conveyance. Use of any of the five triage tools at the pre-specified thresholds would 
potentially improve upon the sensitivity of existing EMS decision making. However, use of PMEWS, 
the WHO algorithm or NEWS2 would lead to up to a 10% increase in ED conveyances (Table 2). Use 
of both CRB65 and the PRIEST score would lead to improvements in sensitivity without sacrificing 
specificity. CRB65 achieved the highest specificity of any of the tools (0.54 95% CI: 0.53 to 0.54) and 
its use would reduce the number of patients conveyed to hospital by around 10%. However, patients 
not conveyed to hospital would have around a 4% risk of subsequently deteriorating. The PRIEST 
tool achieved a sensitivity of 0.97 (95% CI: 0.97 to 0.97) without increasing the number of patients 
transported to hospital. Using the PRIEST tool, patients who were not conveyed to hospital would 
have a 2% risk of subsequent deterioration (compared to an estimated 8% on EMS decision making 
in this cohort).  
Strengths and limitations 
Previous evaluations of triage tool accuracy and prognostic COVID-19 prognostic research in the pre-
hospital setting, are limited by only including patients who were subsequently admitted to 
hospital.22-25  This is the first evaluation to use a large cohort of patients identified from routinely 
collected EMS records and linked to nationally collected, patient-level, healthcare data to provide 
robust outcome data for all patients including those not conveyed to hospital. We had low rates of 
missing data in the variables used in the triage tools assessed (Table 1). We also assessed the 
performance of triage tools in a cohort of patients with suspected infection which, in the absence of 
accurate universally available rapid COVID-19 diagnostic tests, reflects the population which EMS 
staff must clinically triage. Most existing research either aimed to determine if patients with 
suspected infection have COVID-19, or to risk stratify patients with confirmed infection in a hospital 
setting.26  
Our evaluation of triage tool accuracy is limited to a single ambulance service, albeit one covering a 
large population across the North of England, so the results may not be generalisable to other 
healthcare settings. Other ambulance services may serve populations with a different risk-profile, 
provide different types of EMS response or have different thresholds and guidelines regarding when 
to convey patients to hospital. The population used is likely to be have similar baseline 
characteristics to that used to derive and validate the PRIEST score in an ED population, as it was 
conducted at the same time at hospitals in the region (and elsewhere in the UK).
10
 A sensitivity 
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analysis in which patients recruited to the ED-based PRIEST study were removed from analysis, did 
not affect estimates of triage tool performance. The PRIEST tool may perform less well if applied to a 
different, especially non-UK, health care setting.   
We assumed that if co-morbidities were not recorded in routine data within the previous 12-months 
of the index event, they were not present. Our cohort is based on the clinical impression of likely 
COVID infection as determined by EMS crews. This is partly determined by prevalence of COVID-19 
infection which varied during the study period however YAS guidance stated possible COVID-19 
infection should be considered in all patients with shortness of breath, cough or fever and in 
patients with a history of close contact with someone with these symptoms. 
Implications 
Clinical tools should be used in conjunction with clinical decision making when determining whether 
a patient needs to be conveyed to hospital by EMS crews. As previously highlighted, there may be 
good clinical reasons why patients who subsequently deteriorated were not conveyed to hospital in 
this cohort. Within this limitation, our study provides evidence that use of existing clinical triage 
tools may improve clinical decision making in a prehospital setting where the prevalence of serious 
adverse outcomes is similar to the ED.  
In health care contexts where minimising risk of adverse outcomes in those not conveyed to hospital 
is the priority, use of PMEWS or the WHO criteria may be recommended, as they appear to optimise 
sensitivity. Use of the COVID-specific PRIEST tool would achieve almost the same gains in sensitivity 
(0.97 versus 0.98) without leading to a corresponding increase in patients being unnecessarily 
conveyed to hospital. The use of CRB65 would maximise specificity over gains in sensitivity, with a 4% 
risk of adverse outcomes in patients left to self-care in the community. This may be appropriate in 
resource constrained health care contexts and, as oxygen saturations do not form part of the 
assessment tool, it can be practically applied to a large range of health care settings.  
Further research assessing triage tool performance alongside clinical judgement in the prehospital 
setting would be helpful to determine whether triage tools would improve accuracy of decisions to 
transfer patients to hospital in practice. Given the high prevalence of adverse outcomes in this 
cohort, the findings may not be applicable to other lower risk community settings (e.g. patients 
being assessed by general practitioners) and therefore similar research is needed for these 
populations. 
Conclusion 
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The NEWS2, PMEWS, PRIEST tool and WHO algorithm achieved high estimated sensitivities (>0.95) 
with respect to death or organ support, and specificities ranging between 0.3 (NEWS2) and 0.41 
(PRIEST tool). EMS decision to transfer patients to hospital achieved a sensitivity of 0.84 (95% CI 0.83 
to 0.85). Although, there may be good clinical reasons why patients who deteriorated were not 
conveyed to hospital, use of these triage tools would potentially improve EMS triage of patients with 
suspected COVID-19 infection. Use of the PRIEST tool would lead to significant gains in sensitivity 
without increasing the number of patients conveyed to hospital. 
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